Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap7.82B
Enterprise Value7.27B
Trailing P/E37.86
Forward P/E18.93
KRYS
(NASDAQ)Krystal Biotech, Inc.
$260.95-- (--)
Loading... - Market loading
Krystal Biotech (KRYS) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)19.93
Forward Price/Sales14.88
Price/Book (mrq)6.36
Price/Tangible Book (mrq)6.36
Price/FCF (ttm)41.05
Price/OCF (ttm)38.61
PEG Ratio0.29
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue18.68
EV/Earnings35.48
EV/EBITDA45.07
EV/EBIT45.93
EV/FCF38.47
Stock Price
Current price, 52-week range, and moving averages
Current Price$260.95
1-Day Change0.23%
52-Week High$298.30
52-Week Low$122.80
52-Week Change48.30%
YTD Change4.86%
1-Year Change43.04%
50-Day MA$265.90
200-Day MA$204.55
Avg Volume (30 day)203.76K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding29.95M
Book Value per Share$40.72
Net Cash per Share$16.51
FCF per Share$6.31
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$326.25
Target Upside/Downside25.02%
Analyst ConsensusStrong Buy
Analyst Count9
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin92.97%
EBITDA Margin (ttm)41.44%
EBIT Margin (ttm)40.66%
Operating Margin (ttm)41.45%
Pretax Margin (ttm)48.69%
Profit Margin (ttm)52.64%
FCF Margin (ttm)48.55%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)16.80%
Return on Assets (ttm)15.36%
Return on Invested Capital (ttm)23.35%
Return on Capital Employed (ttm)12.86%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue389.13M
Gross Profit361.76M
Operating Income161.29M
Pretax Income189.47M
Net Income204.83M
EBITDA161.26M
EBIT158.24M
Diluted EPS$6.84
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow200.87M
Capital Expenditures11.95M
Free Cash Flow188.91M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth33.94%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)1.33B
Cash & Securities (mrq)496.30M
Net Cash (mrq)494.53M
Net Cash per Share$16.51
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)9.34M
Working Capital (mrq)921.66M
Total Equity (mrq)1.22B
Book Value per Share$40.72
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)9.95
Quick Ratio (mrq)9.56
Debt/Equity (mrq)0.01
Debt/EBITDA (ttm)0.06
Debt/FCF (ttm)0.05
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield2.64%
FCF Yield2.44%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score42.27
Piotroski F-Score5/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Lynch Fair Value$892.83
Lynch Upside/Downside244.84%
Graham Number$79.16
Graham Upside/Downside-69.43%
Frequently Asked Questions About Krystal Biotech Statistics
What are the key financial metrics for KRYS?
Krystal Biotech, Inc. (KRYS) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is KRYS's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Krystal Biotech is overvalued or undervalued.
How do I read KRYS's profitability ratios?
Krystal Biotech's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do KRYS's debt ratios indicate?
The financial health section shows Krystal Biotech's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is KRYS's dividend analysis?
The dividend section covers Krystal Biotech's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.